WaveMan
WaveMan · Company
NGNE · Neurogene Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NGNE Neurogene (NGNE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001404644
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
61
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $19.1K priced

What the filings say about NGNE

Insiders, 180 days
-$640.0K net sold
1 seller · 0% of sales under a 10b5-1 plan

Neurogene insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Neurogene Inc. insiders sold a net $640.0K of stock across 25 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Cvijic Christine Mikail
President and CFO
SELL
2026-07-07 SEC
4,200
$151.8K
-38.4%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (1 buy, 12 sales), the last on Jul 6, 2026.
  • The trade is 5.0% of the 84,040 shares held after it.
  • No other insider sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CFO Cvijic Christine Mikail sold about $151.8K of NGNE on Jul 7, 2026; 61 funds added in the latest 13F quarter.
Cvijic Christine Mikail
President and CFO
SELL
2026-07-07 SECtraded 2026-07-06
600
$21.6K
-38.4%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (1 buy, 11 sales), the last on Jul 2, 2026.
  • The trade is 0.7% of the 88,240 shares held after it.
  • No other insider sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CFO Cvijic Christine Mikail sold about $21.6K of NGNE on Jul 6, 2026; 61 funds added in the latest 13F quarter.
Cvijic Christine Mikail
President and CFO
SELL
2026-07-02 SEC
2,531
$87.5K
-27.7%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Jul 1, 2026.
  • The trade is 2.8% of the 90,370 shares held after it.
  • No other insider sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CFO Cvijic Christine Mikail sold about $87.5K of NGNE on Jul 2, 2026; 61 funds added in the latest 13F quarter.
Cvijic Christine Mikail
President and CFO
SELL
2026-07-02 SEC
1,530
$53.9K
-27.7%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Jul 1, 2026.
  • The trade is 1.7% of the 88,840 shares held after it.
  • No other insider sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CFO Cvijic Christine Mikail sold about $53.9K of NGNE on Jul 2, 2026; 61 funds added in the latest 13F quarter.
Cvijic Christine Mikail
President and CFO
SELL
2026-07-02 SECtraded 2026-07-01
739
$25.2K
-27.7%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on May 6, 2026.
  • The trade is 0.8% of the 92,901 shares held after it.
  • No other insider sold within 30 days.
  • 61 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CFO Cvijic Christine Mikail sold about $25.2K of NGNE on Jul 1, 2026; 61 funds added in the latest 13F quarter.
25 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 20 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$640.0K over 180 days
below 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
61 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
-100.0% year over year
the lowest in Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
44.0% of the float short (float per yahoo 2026-10-26) · 11.7 days to cover · settled 2026-09-30
more than 98% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 7 in the prior 90
Why it matters
The absence is the signal: 7 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch NGNE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.0%12M
-43%-12%+18%+49%2025-102025-122026-022026-042026-062026-082026-10 2026-05-06 · Cvijic Christine Mikail sold $155.7K2026-07-07 · Cvijic Christine Mikail sold $151.8K2026-05-06 · Cvijic Christine Mikail sold $144.3K2026-02-27 · Cvijic Christine Mikail sold $120.5K2026-07-02 · Cvijic Christine Mikail sold $87.5K2026-03-13 · Cobb Stuart sold $81.5K2026-03-26 · McMinn Rachel sold $74.0K2026-03-13 · Cobb Stuart sold $56.7K2026-03-26 · Cvijic Christine Mikail sold $55.3K2026-07-02 · Cvijic Christine Mikail sold $53.9K2026-03-13 · Cvijic Christine Mikail sold $48.7K2026-03-13 · Cvijic Christine Mikail sold $29.6K2026-07-01 · Cvijic Christine Mikail sold $25.2K2026-07-06 · Cvijic Christine Mikail sold $21.6K2026-03-26 · Jordan Julie sold $18.1K2026-03-13 · Cvijic Christine Mikail sold $5.8K2026-03-13 · Cobb Stuart sold $3.3K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NGNE: institutional holders (13F)

13F holdings, latest reported quarter
SAMSARA BIOCAPITAL, LLC
1,717,127 sh
$54.0M
Casdin Capital, LLC
1,545,361 sh
$48.6M
Redmile Group, LLC
1,412,199 sh
$44.4M
RTW INVESTMENTS, LP
1,362,456 sh
$42.8M
EcoR1 Capital, LLC
1,271,342 sh
$40.0M

Congress trades in NGNE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NGNE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NGNE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Meridian Small Cap Growth Fund
$2.4M position · as of 2026-06-30
0.9%
Virtus Biotech Clinical Trials Etf
$351.3K position · as of 2026-07-31
0.8%
Franklin Biotechnology Discovery Fund
$7.2M position · as of 2026-07-31
0.6%
Ultra-Small Company Market Fund
$590.7K position · as of 2026-06-30
0.4%
ALPS Medical Breakthroughs ETF
$452.5K position · as of 2026-05-31
0.3%
Fidelity Advisor Biotechnology Fund
$5.8M position · as of 2026-07-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
1
Phase 3
1 active
1
Not applicable
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr.Mc Minn
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$3.5M
$2.7M
$2.9M
+125%
n/a
2022
$902.2K
-$3.6M
$1.0M
-89%
n/a
2021
$2.7M
-$9.6M
$3.5M
-66%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $640.0K sold by insiders over 180 days, 61 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NGNE financials

Revenue growth
-100.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$87.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-45.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-41.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-48.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-18.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$925.0K$0n/a
Operating income-$103.3M-$82.6M-$55.6M-$56.5M
Net income-$90.4M-$75.1M-$36.3M-$55.2M
EPS (diluted)-4.24-4.28n/a-1.04
Operating cash flow-$77.2M-$70.6M-$51.4M-$52.8M
Cash$103.8M$136.6M$148.2M$82.0M
SEC XBRL, fiscal years, as known on 2026-10-28

NGNE Stock Sonar score 5/7 axes

Find similar shapesCompare

NGNE ranks highest on profitability (54th percentile) and institutional and government (52nd), and lowest on growth (1st), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
54
Inputs
  • Return on equity-45.3% · 57 pct, sector of 545
  • Return on assets-41.0% · 52 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-48.1% · 53 pct, sector of 576
Growth
0
Inputs
  • Revenue growth, YoY-100.0% · 0 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
20
Inputs
  • Net Form 4 buying (codes P and S), 180d-$640K · 40 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
52
Inputs
  • Funds adding, latest quarter61 · 52 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
18
Inputs
  • Short interest, % of float+44.0% · 1 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.6% · 35 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NGNE filings, in plain words

Are Neurogene insiders buying or selling NGNE?

In the 180 days to 2026-10-28, Neurogene insiders were net sellers, a net $640.0K across purchases and sales reported on Form 4, by 1 seller.

Read the full summary

In the 180 days to 2026-10-28, Neurogene insiders were net sellers of NGNE, a net $640.0K across purchases and sales reported on Form 4 by 1 seller. None of the 7 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies